Pentair plc filed a Form 8-K on September 22, 2026, disclosing the appointment of Robert W. Hau as Executive Vice President and Chief Financial Officer, effective November 1, 2026, at which time Interim CFO Robert P. Fishman will resign from that role.
U.S. GoldMining Inc. filed a Form 8-K on September 22, 2026, disclosing the completion of its 2026 drill program targeting high-priority porphyry centers at its Whistler Gold-Copper Project in Alaska.
Circle Internet Group, Inc. filed a Form 8-K on September 22, 2026, disclosing a five-year expanded commercial arrangement with Binance and a concurrent private placement of Class A common stock to Binance for aggregate proceeds of $100 million.
AutoZone, Inc. filed a Form 8-K on September 22, 2026, disclosing that it issued a press release announcing earnings for the fiscal quarter ended August 29, 2026.
Cognex Corporation filed a Form 8-K with the SEC on September 22, 2026, disclosing a definitive agreement to acquire RealSense, Inc. in an all-cash transaction valued at $500 million.
Cypherpunk Technologies Inc. filed a Form 8-K with the SEC on September 22, 2026, disclosing the appointment of Amanda Fabiano as a Class III director on the company's Board of Directors, effective immediately.
Lexeo Therapeutics, Inc. filed an 8-K with the SEC on September 22, 2026, disclosing that it entered into an Agreement and Plan of Merger with Mantle Therapeutics Inc. on September 16, 2026, under which Mantle would become a wholly owned subsidiary of Lexeo.
Tonix Pharmaceuticals Holding Corp. filed a Form 8-K on September 22, 2026, disclosing that it entered into a new agreement with a pharmacy benefit manager providing coverage of TONMYA to approximately 21 million Medicare Part D plan beneficiaries, effective immediately.
Ligand Pharmaceuticals Incorporated filed a Form 8-K on September 22, 2026, disclosing that it acquired royalty and milestone payment rights relating to Santen Pharmaceutical Co., Ltd.'s Ryjunea® from Sydnexis, Inc. for $23 million upfront.
Viking Therapeutics, Inc. filed a Form 8-K with the SEC on September 22, 2026, reporting that the company issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735.